Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2006
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The lead clinical program is indiplon, a candidate for insomnia treatment. The company currently has eight programs in various stages of development.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Balance Sheet (Sep 30, 2006) |
|---|---|---|---|
| Total Revenues | $1,074 | $29,794 | - |
| Net Loss | $(39,143) | $(92,493) | - |
| Loss Per Share (Basic/Diluted) | $(1.03) | $(2.46) | - |
| Operating Expenses | $41,270 | $126,848 | - |
| Cash and Cash Equivalents | - | - | $75,760 |
| Short-term Investments | - | - | $124,018 |
| Total Debt (Current + Long-term) | - | - | $54,992 |
| Accumulated Deficit | - | - | $(392,639) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped significantly from $64.7 million (Q3 2005) to $1.1 million (Q3 2006) and from $109.8 million (9M 2005) to $29.8 million (9M 2006). This is primarily due to the absence of a $50 million milestone payment and $8 million in sales force allowance revenue recognized in 2005 under the Pfizer collaboration.
- Net Loss vs. Income: The company reported a net loss of $39.1 million for Q3 2006, compared to net income of $26.2 million in Q3 2005. For the nine-month period, the net loss was $92.5 million versus net income of $1.7 million in the prior year.
- Restructuring Charges: A one-time charge of approximately $9.5 million was recorded in Q3 2006 related to the termination of the entire sales force and a reduction of approximately 100 R&D and G&A employees.
- Accounting Changes: Adoption of SFAS 123R (Share-Based Payment) effective January 1, 2006, resulted in additional non-cash compensation expenses of $3.2 million (Q3) and $12.7 million (9M).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Indiplon Regulatory Status: The FDA issued an "Approvable" letter for indiplon capsules (5mg and 10mg) and a "Not Approvable" letter for 15mg tablets in May 2006. The company is conducting additional data analysis and a 3-month safety/efficacy study. The capsule NDA is targeted for resubmission in summer 2008. The tablet NDA requires additional long-term safety data and a separate dose for the elderly.
- Pfizer Collaboration Termination: The collaboration with Pfizer to develop and co-promote indiplon was terminated effective December 19, 2006. Neurocrine will reacquire all worldwide rights and is responsible for future development costs. Pfizer ceased reimbursement of the sales force as of July 1, 2006.
- Financial Outlook: Management expects a net loss of approximately $115 million for fiscal year 2006. The company anticipates operating losses for the foreseeable future due to decreased collaboration revenue and increased costs for indiplon resubmission and other pipeline programs.
- Liquidity: As of September 30, 2006, cash and short-term investments totaled $199.8 million. Management believes this is sufficient to fund operations for at least the next 12 months but may require additional funding for long-term development.
Risks and Contingencies
- Regulatory Risk: Failure to obtain FDA approval for indiplon or delays in the resubmission process could severely harm the business. The FDA may require additional clinical trials upon resubmission.
- Commercialization Risk: Without the Pfizer partnership, Neurocrine must find a new partner or build its own commercial infrastructure to market indiplon.
- Asset Impairment: The company holds a $94 million prepaid royalty asset related to indiplon. While no impairment was recognized as of September 30, 2006, future FDA actions or commercialization failures could trigger a material impairment charge.
- Capital Requirements: Additional equity or debt financing may be required, which could be dilutive or restrictive.
Investor Verification Checklist
- Indiplon Resubmission Timeline: Verify the status of the additional 3-month safety study and the feasibility of the summer 2008 resubmission target for capsules.
- Cost of Resubmission: Confirm the estimated costs for the additional data analysis and clinical trials required for both capsule and tablet NDAs.
- Partnership Strategy: Assess the company's progress in identifying a new commercial partner for indiplon or the plan to build an internal sales force.
- Prepaid Royalty Valuation: Monitor the quarterly assessment of the $94 million prepaid royalty asset for potential impairment triggers.
- Cash Burn Rate: Track the monthly cash burn rate to ensure the $199.8 million liquidity position remains sufficient for the projected 12-month runway.